Fazle Husain

Fazle Husain is a Partner and Head of US Healthcare at CVC Capital Partners, a global private equity firm with a network of 23 offices and over 400 employees throughout Europe, Asia and the US. The CVC Group manages over $50 billion of assets. Prior to joining CVC Capital, Mr. Husain was a Managing Director at Metalmark Capital from 2007-2016, and was responsible for leading their effort in healthcare. Before Metalmark Capital, he was also with Morgan Stanley & Co. in the private equity business, where he spent 18 years.

Mr. Husain has a successful track record of investing in healthcare companies for over 25 years, including investments in the healthcare service, medical device, specialty pharmaceuticals, and healthcare information technology sectors. He has invested in and served on the Boards of several private and public companies including Allscripts (MDRX), Cross Country Healthcare (CCRN), Bostwick Laboratories, The Medicines Company (MDCO), Cardiac Pathways (sold to Boston Scientific), Suros Surgical (sold to Hologic), Healthstream (HSTM), Quintiles Transnational, Cytyc Corp (sold to Hologic), Aegis Sciences, IntegraMed America, Vanguard Healthcare Systems (sold to Tenet), and SouthernCare. He was the Chairman of the Board of Healogics (2008-2014), and the Chairman of the Board of Collagen Matrix (2014-2016).

Mr. Husain received an Sc.B. degree in Chemical Engineering from Brown University, and an M.B.A. from Harvard Business School.  He is on the Board of Advisors for The School of Engineering at Brown University. He lives in New York City with his wife and three children.